$VALN News
Last published 2d ago
- 2d agoVALNValneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®GlobeNewswire94% of participants maintained seroresponse five years after a single vaccinationComparable antibody persistence observed in older (65+) and younger adultsData further reinforce IXCHIQ®'s differentiated profile with
- 2d agoVALNValneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®GlobeNewswireLyon (France), November 10, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive five-year antibody persistence data for its single dose chikungunya vaccine IXCHIQ ® . The results demonstrate durable antibody persistence across all age groups evaluated and are consistent with previously reported persistence results 1 , 2 , 3 , 4 . The results ...
- 3d agoVALNValneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2GlobeNewswireData from infant immunogenicity and safety trial, and controlled human infection model (CHIM) trial, demonstrate favorable safety profile with encouraging...
- 3d agoVALNValneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2GlobeNewswireData from infant immunogenicity and safety trial, and controlled human infection model (CHIM) trial, demonstrate favorable safety profile with encouraging immunogenicity and efficacy signals Lyon (France), November 9,
- 1w agoVALNValneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026GlobeNewswireLyon (France), November 4, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that it will report its nine-month 2026 financial results on Tuesday, November 24, 2026. The Company
- 4w agoVALNValneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare ConferencesGlobeNewswireLyon (France), October 14, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that its senior management will present and participate in meetings with institutional investors at
- 1mo agoVALNValneva Provides Update on IXCHIQ® in the United KingdomGlobeNewswireLyon (France), October 07, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that, following a further benefit-risk assessment of IXCHIQ® for travelers by the United Kingdom’s (UK)
- 3mo agoPFEVALNPfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines AgencyGlobeNewswireSubmission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced that the
- 3mo agoPFEVALNPARIS:VLAPfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines AgencyBusiness WireSubmission based on favorable efficacy and safety results from Phase 3 VALOR trial Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced that the European Medicines Agency (EMA) has
- 3mo agoVALNValneva Reports Half Year 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireTotal product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and
- 3mo agoVALNValneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026GlobeNewswireLyon (France), July 22, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that it will report its first half 2026 financial results on Thursday, August 13, 2026. The Company will
- 4mo agoVALNValneva Announces Successful Outcome of its Annual General MeetingGlobeNewswireDr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that shareholders approved all
- 5mo agoVALNValneva Announces Availability of Documentation for its Annual General MeetingGlobeNewswireLyon (France), June 4, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company ("the Company"), today announced the availability of documentation for its Annual General Meeting ("the Meeting") to be held
- 5mo agoVALNValneva to Participate at U.S. and European Investor Conferences in JuneGlobeNewswireLyon (France), May 28, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences
- 6mo agoVALNValneva Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireTotal product sales of €30.5 million Cash position of €105.3 million as of end March 2026, excluding proceeds from successful reserved offering completed in April 20261Program launched in April to further reduce
- 6mo agoVALNValneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026GlobeNewswireLyon (France), May 05, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026. The Company will
- 6mo agoVALNValneva Announces the Successful Completion of an €84 million Reserved OfferingGlobeNewswireValneva Announces the Successful Completion of an €84 million Reserved Offering Lyon (France), April 30, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA) ("Valneva" or the "Company"), a specialty vaccine company, announces
- 7mo agoVALNValneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DCGlobeNewswireLyon (France), March 26, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will take place from March 31 to
- 7mo agoPARIS:VLAPFEVALNPfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR TrialBusiness WireVaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated with no safety
- 7mo agoVALNElaris Secures Exclusive Global License from Valneva for C. difficile Vaccine ProgramPR NewswireElaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive...
- 8mo agoVALNValneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026GlobeNewswireLyon (France), March 9, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that it will report its full year 2025 financial results on Wednesday, March 18, 2026. The Company will
- 8mo agoVALNValneva to Participate in Upcoming Investor ConferencesGlobeNewswireLyon (France), March 2, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in the United
- 8mo agoVALNValneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 OutlookGlobeNewswireTotal Revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing
- 9mo agoVALNValneva Provides Update on Recommendations for Use of IXCHIQ® in the United KingdomGlobeNewswireLyon (France), February 13, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company's single‑dose chikungunya vaccine,
- 9mo agoVALNValneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®GlobeNewswireLyon (France), Sao Paulo, (Brazil), February 3, 2026 –Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research centers, today announced the
- 9mo agoVALNValneva Provides Update on Chikungunya Vaccine IXCHIQ®GlobeNewswireCompany voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and commercial attractiveness Saint Herblain (France), January 19, 2026 – Valneva SE
- 10mo agoVALNValneva to Meet with Investors during the J.P. Morgan Healthcare ConferenceGlobeNewswireSaint Herblain (France), January 09, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that members of its management team will meet one-on-one with existing shareholders and hold
- 11mo agoVALNValneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®GlobeNewswireIXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups, although more
- 11mo agoVALNValneva to Further Consolidate its Operations in FranceGlobeNewswireFrench operations to be concentrated at its Lyon site Final consolidation of R&D in Vienna Saint-Herblain (France), November 26, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced a strategic initiative
- 11mo agoVALNValneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine CandidateGlobeNewswireAntibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo safety concerns observed in any age group by an independent Data Monitoring Committee
- 11mo agoVALNValneva Reports Nine-Month 2025 Financial Results and Provides Corporate UpdatesGlobeNewswireTotal revenues of €127.0 million compared to €116.6 million in the first nine months of 2024Cash and cash equivalents of €143.5 million at end of September 2025Financial flexibility enhanced with successful debt
- 1y agoVALNValneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine CandidateGlobeNewswireImmune response successfully improved with second generation vaccine candidate Saint-Herblain (France), November 4, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced positive
- 1y agoVALNValneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare ConferencesGlobeNewswireSaint-Herblain (France), October 27, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional
- 1y agoVALNValneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business UpdatesGlobeNewswireNew debt facility extends repayment from Q1 2026 to Q4 2030, lowers interest rate and provides access to additional capital for future business developmentCompany adjusts 2025 financial guidance and provides key business
- 1y agoVALNValneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®GlobeNewswireLong-lasting antibody persistence was comparable in older (65+) and younger adultsLong-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya
- 1y agoVALNValneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine CandidateGlobeNewswireStrong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypesNo safety concerns observed in any age group by independent Data Monitoring
- 1y agoVALNValneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.GlobeNewswireSaint Herblain (France), August 25, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for
- 1y agoVALNValneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and OlderGlobeNewswireSaint Herblain (France), August 18, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine,
- 1y agoVALNValneva SE (VALN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoVALNValneva Reports Half Year 2025 Financial Results and Provides Corporate UpdatesGlobeNewswireTotal revenues of €97.6 million compared to €70.8 million in the first half of 2024Cash and cash equivalents of €161.3 million at end of June 2025Further clinical and regulatory progress2025 financial outlook confirmed
- 1y agoVALNValneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing InformationGlobeNewswireSaint Herblain (France), August 7, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60
- 1y agoPARIS:VLAVALNAGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine CandidateBusiness WireAGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (NASDAQ:VALN, PARIS:VLA) to supply drug substance for an
- 1y agoVALNValneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in ElderlyGlobeNewswireSaint Herblain (France), July, 11 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating
- 1y agoVALNValneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL SeqirusGlobeNewswireSaint-Herblain, France, June 26, 2025 – Valneva SE, (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world's largest influenza vaccine companies,
- 1y agoVALNValneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidanceGlobeNewswireSaint-Herblain (France), June 25, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders
- 1y agoVALNValneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®GlobeNewswireIXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV)Antibody levels remained high after six months in both dose groups, although more
- 1y agoVALNValneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate UpdateGlobeNewswireSaint-Herblain (France), June 4, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company ("the Company"), today announced the availability of documentation for its Combined General Meeting ("the Meeting")
- 1y agoVALNValneva to Participate at U.S. and European Investor Conferences in JuneGlobeNewswireSaint-Herblain (France), May 26, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor
- 1y agoVALNValneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United StatesGlobeNewswireSaint Herblain (France), May, 12 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and
- 1y agoVALNValneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in ElderlyGlobeNewswireSaint Herblain (France), May, 07 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva's single-dose live